IRVINE, CA, UNITED STATES, October 5, 2026 /EINPresswire.com/ -- Innova Vascular, Inc., a medical technology company developing minimally invasive treatments for blood clots in the vascular system, today announced positive results from its pivotal TRUST (Treating Pulmonary Embolism with Laguna Thrombectomy System) study evaluating the Laguna® Thrombectomy System for the treatment of pulmonary embolism (PE).
The Laguna® Thrombectomy System, comprised of the Malibu® Aspiration Catheter System and the Laguna Clot Retriever® System, was previously cleared by the U.S. Food and Drug Administration (FDA) for use in the peripheral vasculature. The TRUST study was conducted to evaluate the platform for a potential expansion of its indication to include the treatment of pulmonary embolism. Results were presented by Global Co-Principal Investigator S. Jay Mathews, MD, at the Vascular InterVentional Advances (VIVA) conference in Las Vegas.
TRUST was a prospective, single-arm, multicenter pivotal study designed to evaluate the safety and effectiveness of the Laguna® Thrombectomy System in patients with acute pulmonary embolism. The study enrolled 107 patients across 17 centers, including 13 centers in the United States, with participation from 30 operators.